Figure 1
From: Recombinant human MFG-E8 ameliorates colon damage in DSS- and TNBS-induced colitis in mice
rhMFG-E8 ameliorates clinical signs of DSS- and TNBS-induced colitis. C57BL/6 mice were exposed to drinking water containing 4% DSS for 7 consecutive days, and received daily subcutaneous injections of rhMFG-E8 (60 or 120 μg/kg/day) or vehicle (saline) from day 2 to day 7 (n=5/group). BALB/c mice received a single intrarectal dose of TNBS at day 0, and received daily subcutaneous injections of rhMFG-E8 (60 or 120 μg/kg/day) or vehicle (saline) from day 1 to day 6 (n=10/group). (a) Mice exposed to DSS and treated with rhMFG-E8 experienced a dose-dependent reduction in the colitis clinical severity score, a composite measure of weight loss, stool consistency, and blood in the stools. (b) Mice exposed to TNBS and treated with rhMFG-E8 also had a dose-dependent reduction in the colitis clinical severity score, which peaked on day 1 and progressively decreased during the observation period. (c) At day 8, mice exposed to DSS and treated with vehicle had a significant reduction in body weight, while mice treated with rhMFG-E8 had a dose-dependent decrease in weight loss. (d) At day 7, mice exposed to TNBS and treated with vehicle also had a reduction in body weight, while mice treated with rhMFG-E8 also experienced a dose-dependent decrease in weight-loss. Ctrl=control; Veh=vehicle; 60=rhMFG-E8 60 μg/kg/day; 120=rhMFG-E8 120 μg/kg/day; *P<0.05 vs control; #P<0.05 vs vehicle.
